February 8, 2022 -- Biomunex Pharmaceuticals and Institut Curie are collaborating to develop a breakthrough immunotherapy drug candidate for the treatment of hematological malignancies and solid tumors based on Biomunex's proprietary Bixab technology.
CD3-based T-cell redirection is applied to a wide variety of cancer types; however, this approach has many limitations. Biomunex and Institut Curie evaluated the potential of a unique subpopulation of nonconventional T cells to be redirected to kill cancer cells based on Biomunex's bi- and multispecific antibody technology platform, Bixab.
The nonconventional T-cell redirection approach paves the way for safer and more efficacious disruptive immunotherapeutics, the companies said in press release. The collaboration objective is to enter clinical development within the next 24 months.
The nonconventional T-cell redirection approach has received close to 3 million euros ($3.4 million) in grants from the French government as part of the Grand Défi Biomédicament scheme.
Biomunex Pharmaceuticals develops immunotherapoies through the discovery and development of bi- and multispecific antibodies.
Copyright © 2022 scienceboard.net